Who are Betahistine Extended Release formulation's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/betahistine-extended-release-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Betahistine Extended Release formulation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Betahistine Extended Release formulation (Betahistine Extended Release formulation) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histamine H1 receptor agonist / H3 receptor antagonist. Area: Otolaryngology / Neurology.

marketed Histamine H1 receptor agonist / H3 receptor antagonist Histamine H1 receptor, Histamine H3 receptor Otolaryngology / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Betahistine Extended Release formulation (Betahistine Extended Release formulation) — OBEcure Ltd.. Betahistine is a histamine H1 receptor agonist and H3 receptor antagonist that increases blood flow to the inner ear and reduces endolymphatic pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Betahistine Extended Release formulation TARGET	Betahistine Extended Release formulation	OBEcure Ltd.	marketed	Histamine H1 receptor agonist / H3 receptor antagonist	Histamine H1 receptor, Histamine H3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histamine H1 receptor agonist / H3 receptor antagonist class)

OBEcure Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Betahistine Extended Release formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/betahistine-extended-release-formulation. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing